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Abstract 15 
Objective: To validate an alternative method for summing the biologically effective doses of 16 
intensity-modulated arc therapy (IMAT) with interstitial HDR brachytherapy (BT) or IMAT 17 
boost in prostate cancer and compare it to the recent Uniform Dose Conception (UDC) 18 
method. 19 
Methods: Initially 15 IMAT plus interstitial HDR BT plans of patients with intermediate- and 20 
high-risk prostate cancer were included and additional plans of IMAT plus IMAT boost were 21 
created. The prescribed dose was 2/44 Gy for the whole pelvis, 2/60 Gy for the prostate and  22 
vesicle seminals and 1x10 Gy for the prostate gland in BT boost or 2/18 Gy for the prostate 23 
PTV in IMAT boost. CT set of teletherapy was registered with the US of BT, and the most 24 
exposed volume of critical organs in BT were identified on these CT images. The minimal 25 
dose of this volumes was calculated in IMAT plans and summed with the dose from BT using 26 
the linear-quadratic radiobiological model. Biological total doses (EQD) were calculated and 27 
compared between plans with BT and IMAT boost. This method was compared with uniform 28 
dose conception (UDC) in IMAT plus BT boost plans. 29 
Results: D90 of the prostate was significantly higher with BT than with IMAT boost: 99.3 Gy 30 
vs. 77.9 Gy, p=0.0034. The dose to rectum and hips were significantly lower with BT boost, 31 
D2 were 50.3 Gy vs. 76.8 Gy (p=0.0117) and 41.9 Gy vs. 50.6 Gy (p=0.0044), respectively. 32 
The dose to bladder showed the same trend, D2 were 73.1 Gy vs. 78.3 Gy in BT vs. IMAT 33 
plans, dose to urethra was significantly higher with BT boost, D0.1 was 96.1 Gy vs. 79.3 Gy 34 
(p=0.0180) using BT vs. IMAT boost technique. UDC overestimates D2 of rectum by 37% 35 
(p=0.0117) and underestimates D0.1 of urethra by 1% (p=0.0277) and D2 of bladder by 7% 36 
(p=0.0614). 37 
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Conclusions: Based on our biological dose summation method, total dose of the prostate is 38 
higher using BT boost, than the IMAT. BT boost yields lower rectum, bladder and hip doses, 39 
but higher dose to urethra. UDC overestimates rectum dose and underestimates the dose to 40 
urethra and bladder. 41 
Keywords: prostate cancer; dose summation; integrated biological doses; intensity-modulated 42 
arc therapy; interstitial brachytherapy 43 
 44 
45 
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Introduction 46 
The standard of care in the curative treatment of intermediate- and high-risk prostate cancer is 47 
external beam radiotherapy (teletherapy, TT) and high-dose-rate (HDR) interstitial 48 
brachytherapy (BT) boost with androgen deprivation therapy. Since the α/β value of prostate 49 
tumour is low, dose escalation has an essential role in the development of both radiotherapy 50 
modalities [1,2]. The more complex the techniques, the more they are capable escalating the 51 
dose to the tumour, while sparing the organs at risk (OARs). The state-of-the-art radiotherapy 52 
combination is intensity-modulated arc therapy (IMAT) and image-guided interstitial BT 53 
[3,4]. These complex treatments require reliable reporting of the dose received by tumour and 54 
the critical structures. 55 
 The use of BT boost has been linked with improved biochemical-progression-free and 56 
overall survival [5,6]. What is more, modern HDR BT approach results in improved quality of 57 
life, as a consequence of lower acute urinary and rectal toxicity [7], with the dose coverage of 58 
the target volume (D90, the minimum dose delivered to 90% of the prostate) correlating with 59 
local tumour control [8], and dose of the OARs with normal tissue toxicity [9]. 60 
To achieve reporting these dose-volume parameters properly, overall volumetric doses 61 
have to be properly integrated from tele- and brachytherapy. As simple physical dose 62 
summation does not take into consideration the different biological effects, the equivalent 63 
dose given in 2 Gy fractions (EQD2) has to be calculated [10,11]. The dose distribution of the 64 
TT is assumed to be completely uniform in the target volume and OARs (Uniform Dose 65 
Conception, UDC) [12]. However, in the IMAT technique the most exposed 2 ccm of the 66 
OARs is not a compact volume, since its voxels are dispersed in the organ, as we have shown 67 
earlier [13]. It was also shown that the most exposed part of the OARs in the integrated plans 68 
is located in the same region that receives the largest dose in BT. Nevertheless, this 2 ccm 69 
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volume is not in the same location, as the most exposed part in TT [14]. So simple DVH 70 
addition sums the dose of two different 2 ccm volumes. 71 
In the majority of previous investigations authors did not take into account the real 72 
biological dose of the prostate and the OARs in TT in combined TT and BT treatment. 73 
Pinkawa et al. [15] used the above mentioned UDC method to estimate the doses from TT and 74 
engaged physical BT doses only. Andrzejewski et al. [16] compared different advanced 75 
radiotherapy methods for boosting dominant intraprostatic lesion. They calculated biological 76 
equivalent doses for comparison but did not examine combined therapies. Kikuchi et al. [17] 77 
made a CT series after BT and calculated the biological effective dose of the rectum in TT 78 
and BT. They associated this dose to the pixels of the rectum volume and computed a 79 
summarised dose-volume histogram (DVH) of TT and BT based on this. This was a better 80 
estimation of the rectal dose, than the UDC method, but they could not take into consideration 81 
the quadratic behaviour of the biological dose. This biological dose has to be calculated pixel-82 
by-pixel in the same organ, but currently in none of the treatment planning systems this 83 
feature is available. The image registration of the TT CT and the CT after BT treatment does 84 
not use the dose values from the real BT plan. The dose gradient is high in BT, so the dose 85 
distribution can be significantly different in a post-BT plan without the needles and the US 86 
probe than in the live plan. Using doses of the live plan, where the needles is in their real 87 
place, is the most adequate method. 88 
We have developed an alternative dose summation method in combined radiotherapy 89 
of cervical cancer [14]. The aim of the present study is to validate an alternative method for 90 
summing the biologically effective doses of IMAT with interstitial HDR BT or IMAT boost 91 
in prostate cancer and compare it to the recent UDC method. 92 
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Materials and methods 93 
At our institute, fifteen IMAT plus interstitial HDR BT plans of patients with intermediate- 94 
and high-risk prostate cancer were included for this study. Selection criteria were the 95 
following: PSA>10 ng/mL and/or GS 7-10 and/or Stage T2b-T3b. The TT was performed in 96 
supine position, the patients were immobilized with knee and ankle support system. The 97 
prescribed dose was 2/44 Gy for the whole pelvis, 2/60 Gy for the prostate and the vesicle 98 
seminals and was delivered with an energy of 10 MV using 2 full arcs. Based on our local 99 
IGRT protocol, CBCT verification was made from 1st to 3rd fractions, the systematic error was 100 
calculated and corrected before the 4th fraction, then weekly verification was done for patient 101 
positioning. TT was complemented with transrectal US-guided interstitial HDR BT boost, 102 
performed after the 4 weeks TT course, given 1 fraction of 10 Gy [18]. After scanning the 103 
prostate with US, a virtual preimplant plan was generated (Oncentra Prostate v3.1, Elekta 104 
Brachytherapy, Veendendaal, The Netherlands). HIPO optimization method was used, and the 105 
prescribed dose was 10 Gy to the whole prostate gland (V100≥95%). Based on this plan, 106 
metal needles were inserted into the prostate through a template under live US guidance. The 107 
optimization procedure was used again for calculating the dwell times in the inserted needles 108 
to achieve the final dose distribution. The detailed description of our treatment method can be 109 
found in our previous publications [19,20]. The total treatment time of TT and BT was 7 110 
weeks (44-54 days). In clinical routine, the EUD method was used to determine the dose 111 
constraints for prostate and OARs in BT implant and their total doses. 112 
First, the treatment planning CT for TT was registered with the US set of BT in BT 113 
treatment planning system in every case (Figure 1), then the TT CT with the BT plan was 114 
imported to the TT planning system (Eclipse v13.7, Varian Medical Systems, Palo Alto, 115 
USA). 116 
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Then, the localisation of the most exposed part of the OARs was investigated in the sum 117 
of TT and BT plans. The most exposed part of hips (femoral heads) is always the nearest 118 
volume to the prostate and the dose contribution from BT is practically zero. So, the most 119 
exposed 0.1 and 2 ccm of hips were calculated only from the TT plan. The most exposed part 120 
of the rectum, urethra and bladder is in the region where the dose maximum is in BT. So, the 121 
most exposed 0.1 and 2 ccm from BT were determined in the TT CTs, and the intersection of 122 
this volumes and the given organ was created (Figure 2). The minimal dose of this 123 
intersection was calculated in TT plans and summed with the dose of this volumes from BT 124 
using the linear-quadratic radiobiological model. The α/β of prostate tumour was assumed 1.5 125 
Gy, while for OARs 3 Gy was used. The following dose-volume parameters were used for 126 
quantitative evaluation of the plans: 127 
D90: the minimum dose delivered to 90% of prostate (Gy); 128 
D0.1(x): the minimal dose of the most exposed 0.1 ccm of the critical organ x (Gy), 129 
where x: rectum, urethra, bladder or hips. 130 
D2(x): the minimal dose of the most exposed 2 ccm of the critical organ x (Gy), 131 
where x: rectum, bladder or hips. 132 
To patients, whom BT is not accomplishable, TT boost is performed with additional 18 133 
Gy in 2 Gy fractions for the prostate gland using safety margins of 0.5 cm, if gold markers are 134 
implanted into the prostate, and 0.8 cm, if not [21,22]. For comparison, additional TT boost 135 
plans were created for every patient in the study with the same IMAT technique, and total 136 
EQD2 doses of the most exposed volume of the organs at risks were calculated in these 3-step 137 
TT plans. 138 
Wilcoxon-matched pairs test was used (Statistica 12.5, StatSoft, Tulsa, OK, USA) to 139 
compare biological total dose of the combination of TT and BT or TT boost in the treatment 140 
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of prostate tumour. The comparison of our biological dose summation (BDS) and the 141 
conventional UDC method was also performed with this statistical test. 142 
Results 143 
The mean volume of the prostate was 29.8 ccm (21.1-43.0 ccm). We found that EQD2 D90 of 144 
the prostate was 99.3 Gy (96.8-101.9 Gy) using two-step TT and BT boost. The D0.1 and D2 of 145 
rectum were 62.8 Gy (41.0-75.6 Gy) and 50.3 Gy (29.8-65.8 Gy). The D0.1 of urethra was 146 
96.1 Gy (95.5-96.9 Gy), the volume of it was less than 2 ccm in our cases. The D0.1 and D2 of 147 
bladder were 85.8 Gy (62.5-169.8 Gy) and 73.1Gy (46.0-140.5 Gy). The D0.1 and D2 of hips 148 
were 49.6 Gy (39.8-67.3 Gy) and 41.9 Gy (33.5-58.3 Gy). 149 
In TT boost, the volume of the PTV is larger than the prostate, it was 111.7 ccm on 150 
average (range: 71.9-179.5 ccm). In comparison of BT and TT boost techniques, D90 of the 151 
prostate was significantly higher with BT than with TT: 99.3 Gy vs. 77.9 Gy, p=0.0034. The 152 
dose to rectum and hips were significantly lower with BT boost, D2 was 50.3 Gy vs. 76.8 Gy 153 
(p=0.0117) and 41.9 Gy vs. 50.6 Gy (p=0.0044), respectively. The difference between the 154 
dose to bladder in the case of BT and TT boost showed the same trend, D2 was 73.1 Gy vs. 155 
78.3 Gy in BT vs. TT plans, but this difference was not significant. Nevertheless, the dose to 156 
urethra was significantly higher with BT boost, D0.1 was 96.1 Gy vs. 79.3 Gy (p=0.0180) 157 
using BT vs. TT boost technique (Figure 3). The detailed results can be found in Table 1. 158 
Comparing our dose summation method to the conventional UDC in the case of 159 
combined TT with BT boost, we found that the UDC overestimates D2 of rectum by 37% and 160 
underestimates D0.1 of urethra by 1%. The D2 of bladder was also 7% smaller using UDC, but 161 
this difference was not significant because of the large standard deviation of this variable 162 
(Table 2). 163 
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Discussion 164 
Dose escalation has a fundamental role in the radiotherapy of intermediate- and high-risk 165 
prostate cancer [1,2]. Presently there are no better alternatives of BT boost, however, several 166 
high-tech teletherapy techniques are possible competitors, such as image-guided and 167 
intensity-modulated teletherapy, arc therapy, helical tomotherapy and stereotactic 168 
radiotherapy with linear accelerators or CyberKnife [3,7,16]. 169 
Vanneste et al. [1] have pointed out the strong correlation between overall survival and 170 
D90 of the prostate target volume in localised prostate cancer, with the best results being 171 
achievable above 75.6 Gy EQD2. Different treatment techniques lead to the same cure rate 172 
but with different toxicity pattern. The EQD2 prescribed dose to the prostate with our 173 
fractionation scheme is 92.9 Gy using BT and 78 Gy with TT boost. At the same time dose to 174 
the OARs is reduced with BT [3,4]. In our study, using IMAT TT with HDR BT boost could 175 
be dose of all OARs kept in a good tolerance level. The EQD2 D90 of the prostate was 99.3 176 
Gy, while D2 of rectum was 50.3 Gy, approximately the half of the prostate dose. D0.1 dose to 177 
the urethra was 96.1 Gy on average, less than the prostate dose, in spite of that urethra is 178 
inside the prostate. D2 dose to the bladder was 73.1 Gy, while for hips it was only 41.9 Gy. 179 
All dose to the hips originates from 60 Gy of TT, BT does not contribute to it. 180 
 Notwithstanding, in TT larger target volume is used than BT, the total dose to the 181 
prostate is 22% (21.4 Gy) less, D90 was 99.3 Gy using BT and 77.9 Gy with TT boost. D2 182 
dose to the rectum, bladder and hips were 35% (26.5 Gy), 7% (5.2 Gy) and 18% (8.7 Gy) 183 
smaller with BT, than using TT boost. 18 Gy IMAT boost to the prostate target volume 184 
instead of BT means extra 9 Gy dose to the hips. Only the dose to the urethra was higher with 185 
BT boost, D0.1 was 18% (16.8 Gy) higher than using TT boost. 186 
In previous publications authors used the recommended UDC method to estimate the 187 
total dose of the prostate and OARs in combined therapy [15]. However, they did not take 188 
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into account the real biological doses. Kikuchi et al. [17] tried a better estimation of the rectal 189 
dose, than the UDC method, but they used a CT after removing the needles and the US probe 190 
instead of a postimplant CT or a live US imaging in the intraoperative BT plan and they did 191 
not take into account the quadratic behaviour of the biological dose. Since the most exposed 192 
part of the rectum, urethra and bladder is in the region where the dose maximum is in BT, this 193 
most exposed 2 ccm can be used for the calculation of the total biological dose. In this small 194 
volume, the quadratic dependence is negligible. Thus, our dose summation method is simple, 195 
timesaving and there is no interobserver variation. The only more precise method would be a 196 
pixel-by-pixel calculation of the biological dose in the same organ after a deformable 197 
registration of BT and TT images, but no treatment planning systems provides this possibility 198 
at the moment. 199 
The effect of the dose summation technique on dose-volume parameters in combined 200 
TT and BT was also investigated in our study. The EQD2 D90 of the prostate was practically 201 
equal in our BDS and the conventional UDC method, but UDC overestimates the dose to 202 
rectum by 37% (18.6 Gy) and underestimates the dose to urethra by 1% (0.7 Gy) and dose to 203 
bladder by 7% (4.9 Gy) compared to BDS method. Besides this, the potential advantage of the 204 
BDS method is that it takes into account the most exposed part of the OARs and thus sparing 205 
these parts from higher doses in TT, as is shown in Figure 4. On the whole, the dose to the 206 
OARs can be reduced using our alternative dose summation method. 207 
 This study is the starting point of the development of an algorithm for the summation 208 
of TT and BT biologically effective doses, which uses an artificial-intelligence-based DIR 209 
algorithm to match the critical anatomical structures in the two radiotherapy modalities. 210 
Further investigations are needed to assess whether our method predicts toxicity better than 211 
the recent UDC method. 212 
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Conclusions 213 
Based on our biological dose summation method in IMAT with interstitial HDR BT or IMAT 214 
boost treatment in prostate cancer, total dose of the prostate is higher using BT boost, than the 215 
IMAT. BT boost results lower rectum, bladder and hip doses, but higher dose to the urethra. 216 
UDC overestimates rectum dose and underestimates the dose to the urethra and to the bladder. 217 
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Tables: 311 
EQD2 TT + BT boost TT + TT boost *p-value 
D90 (Gy) 99.3 (96.8-101.9) 77.9 (76.4-78.5) 0.0034 
D2(rectum) (Gy) 50.3 (29.8-65.8) 76.8 (65.8-79.3) 0.0017 
D0.1(urethra) (Gy) 96.1 (95.5-96.9) 79.3 (78.6-80.4) 0.0180 
D2(bladder) (Gy) 73.1 (46.0-140.5) 78.3 (77.2-79.8) 0.1614 
D2(hips) (Gy) 41.9 (33.5-58.3) 50.6 (43.6-58.1) 0.0044 
Table 1. The EQD2 total doses of intensity-modulated arc therapy plus interstitial HDR 312 
BT boost (TT + BT boost) and intensity-modulated arc therapy plus teletherapy boost 313 
(TT + TT boost). D90: the minimum dose delivered to 90% of prostate (Gy), D2(rectum), 314 
D2(bladder), D2(hips): the minimal dose of the most exposed 2 ccm of rectum, bladder 315 
and hips (Gy), D0.1(urethra): the minimal dose of the most exposed 0.1 ccm of urethra 316 
(Gy). *Wilcoxon-matched pairs test. 317 
 318 
EQD2 BDS UDC *p-value 
D90 (Gy) 99.3 (96.8-101.9) 100.2 (96.6-104.8) 1.0000 
D2(rectum) (Gy) 50.3 (29.8-65.8) 68.9 (66.6-70.9) 0.0117 
D0.1(urethra) (Gy) 96.1 (95.5-96.9) 95.4 (94.4-96.0) 0.0277 
D2(bladder) (Gy) 73.1 (46.0-140.5) 68.2 (62.9-74.0) 0.0614 
Table 2. The EQD2 total doses of intensity-modulated arc therapy plus interstitial HDR 319 
BT boost calculated by our biological dose summation (BDS) and the uniform dose 320 
conception (UDC) method. D90: the minimum dose delivered to 90% of prostate (Gy), 321 
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D2(rectum), D2(bladder): the minimal dose of the most exposed 2 ccm of rectum and 322 
bladder (Gy), D0.1(urethra): the minimal dose of the most exposed 0.1 ccm of urethra 323 
(Gy). *Wilcoxon-matched pairs test. 324 
325 
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Figures: 326 
 327 
Figure 1. The BT treatment plan on the registered TT CT and BT US sets. Top left: a 328 
coronal view, top right: 3D reconstruction, bottom left: an axial view, bottom right: a 329 
sagittal view. Thick red: prostate, thick green: rectum, thick yellow: urethra, thick 330 
orange: bladder, green, red and yellow line: the 80%, 100% and 120% isodose line. 331 
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 332 
Figure 2. The most exposed 2 ccm part (pink) of the rectum (brown) in an axial (up), in 333 
a coronal (left) and in a sagittal (right) slice of the TT CT. 334 
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 335 
Figure 3. The EQD2 total doses of intensity-modulated arc therapy plus interstitial HDR 336 
BT boost (BT) and intensity-modulated arc therapy plus teletherapy boost (TT). D90: 337 
the minimum dose delivered to 90% of prostate (Gy), D2(rectum), D2(bladder), D2(hips): 338 
the minimal dose of the most exposed 2 ccm of rectum, bladder and hips (Gy), 339 
D0.1(urethra): the minimal dose of the most exposed 0.1 ccm of urethra (Gy). 340 
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 341 
Figure 4. The most exposed 2 ccm of rectum is indicated with brown, the urethra and 342 
the bladder are contoured with yellow and orange and the prostate gland is shown with 343 
red (colorwash) in an axial (left) and a sagittal (right) CT slice in a two-step intensity-344 
modulated arc therapy plan. Isodose lines: red: 60 Gy, yellow: 57 Gy, blue: 44 Gy and 345 
green: 41.8 Gy. 346 
